New research published in Frontiers in Pharmacology explores the molecular underpinnings of radioiodine-refractory papillary thyroid carcinoma (RAIR PTC) and anaplastic thyroid carcinoma (ATC), two particularly challenging forms of thyroid cancer. This study aims to identify shared transcriptional patterns and leverage them to prioritise targeted drug classes, offering insights for future thyroid cancer treatment research.
Differentiated thyroid carcinoma is often manageable, but a notable number of patients develop RAIR PTC or ATC, which are associated with limited therapeutic options and a poorer prognosis. RAIR PTC is characterised by a loss of radioiodine uptake or a lack of response to standard radioiodine therapy, often leading to increased metastatic potential. ATC is a rarer, highly aggressive form of thyroid cancer, frequently preceded by differentiated disease.
Understanding the RAIR–ATC Transcriptional Axis
The study, conducted by Siying Wang, Dechun Zhang, and colleagues from the Department of Geriatrics, Changde Hospital, Xiangya School of Medicine, Central South University, hypothesised that RAIR and ATC share a common transcriptional axis. By integrating RNA-seq and microarray data from various cohorts, including TCGA-THCA and several RAIR and ATC datasets, researchers derived gene modules associated with these conditions.
- The findings suggest that RAIR and ATC both upregulate modules converging on an epithelial–mesenchymal transition (EMT), angiogenesis, and inflammatory/interferon axis.
- ATC appears to represent a more extreme manifestation of this shared molecular state.
- A specific ‘RAIR signature’ was developed, which could stratify TCGA tumours based on the activation of these biological programs. This signature was largely independent of common genetic alterations like BRAF and TERT promoter status.
This molecular insight into the RAIR–ATC axis provides a more comprehensive understanding beyond single-gene biomarkers, which have often been the focus of previous thyroid cancer treatment research.
Identifying Potential Targeted Therapies
To connect these molecular signatures with potential therapeutic strategies, the researchers applied the RAIR signature to thyroid cancer cell lines available through the Cancer Dependency Map (DepMap). They then combined these RAIR scores with drug-response data from the PRISM drug-repurposing resource.
A multimodal ridge model was trained to predict drug response, integrating both cell features and drug characteristics. This approach aimed to identify drug classes that showed preferential activity in RAIR-high thyroid cell lines.
- VEGFR/KDR (Vascular Endothelial Growth Factor Receptor/Kinase Insert Domain Receptor) inhibitor classes demonstrated preferential activity in RAIR-high thyroid cell lines.
- RAF/BRAF inhibitor classes also showed this preferential activity.
- Initial in vitro validation in a RAIR-high/ATC-like thyroid cancer model provided proof-of-concept support for these predictions, with sorafenib, a RAF–MAPK signalling inhibitor, exhibiting dose-dependent cytotoxicity.
These findings suggest specific drug classes that could be further evaluated for their potential in managing RAIR and ATC, offering a more targeted approach to treatment.
Implications for Future Thyroid Cancer Treatment
The study’s framework, which starts from biologically meaningful modules and uses machine learning to connect them to therapeutic hypotheses, offers a promising direction for future thyroid cancer treatment research. By prioritising VEGFR/KDR and RAF/BRAF inhibitor classes, the research provides candidates for further translational evaluation in RAIR-like thyroid models.
While these findings are encouraging, it is important to note that this is preliminary research. Further clinical trials would be necessary to determine the safety and efficacy of these targeted therapies in patients with RAIR PTC and ATC. The approach highlights the potential of integrating diverse molecular and pharmacological datasets to guide the development of more effective treatment strategies for challenging cancers.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
